A share price of Amylyx Pharmaceuticals Inc [AMLX] is currently trading at $3.48, up 0.87%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AMLX shares have gain 11.18% over the last week, with a monthly amount drifted -11.68%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] stock has seen the most recent analyst activity on November 18, 2024, when Robert W. Baird upgraded its rating to a Outperform and also boosted its price target to $11 from $3. Previously, BofA Securities upgraded its rating to Buy on October 23, 2024, and elevated its price target to $10. On March 18, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $4 on the stock. Robert W. Baird downgraded its rating to a Neutral and decreased its price target to $4 on March 11, 2024. Leerink Partners downgraded its rating to a Market Perform and reduced its price target to $4 on March 11, 2024. Goldman downgraded its rating to Neutral for this stock on March 08, 2024. In a note dated March 08, 2024, Evercore ISI downgraded an In-line rating on this stock.
Amylyx Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $1.58 and $19.95. Currently, Wall Street analysts expect the stock to reach $8.25 within the next 12 months. Amylyx Pharmaceuticals Inc [NASDAQ: AMLX] shares were valued at $3.48 at the most recent close of the market. An investor can expect a potential return of 137.07% based on the average AMLX price forecast.
Analyzing the AMLX fundamentals
Trailing Twelve Months sales for Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] were 196.49M which represents -99.59% decline. Gross Profit Margin for this corporation currently stands at 0.32% with Operating Profit Margin at -1.27%, Pretax Profit Margin comes in at -1.31%, and Net Profit Margin reading is -1.32%. To continue investigating profitability, this company’s Return on Assets is posted at -1.03, Equity is -0.85 and Total Capital is -1.27. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.31 points at the first support level, and at 3.13 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.58, and for the 2nd resistance point, it is at 3.68.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Amylyx Pharmaceuticals Inc [NASDAQ:AMLX] is 4.55. As well, the Quick Ratio is 4.55, while the Cash Ratio is 1.33. Considering the valuation of this stock, the price to sales ratio is 1.52, the price to book ratio is 1.22.
Transactions by insiders
Recent insider trading involved Klee Justin B., Co-Chief Executive Officer, that happened on Jan 06 ’25 when 7471.0 shares were sold. Co-Chief Executive Officer, Cohen Joshua B completed a deal on Jan 06 ’25 to sell 7471.0 shares. Meanwhile, Chief Medical Officer Bedrosian Camille L sold 5421.0 shares on Dec 02 ’24.
